Geron in Boehringer deal to detect telomerase:
This article was originally published in Clinica
Geron and Boehringer Mannheim are collaborating worldwide to develop and commercialise research aimed at monitoring the enzyme telomerase, which is a measure of the presence and severity of cancers. Geron will receive funding and milestone payments, as well as royalties on eventual products. Boehringer will get exclusive rights outside the US on products, and will be responsible for pre-clinical and clinical trials. Both companies will co-promote any eventual products in the US. Telomerase is claimed to be the "universal" cancer marker, having been found where more than 20 different cancer types are present, but not detected in most normal tissue.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.